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ABSTRACT: The cell internalization of designed oligoargi-
nine peptides equipped with six glutamic acid residues and 
an anionic pyranine at the N-terminus is triggered upon 
addition of a supramolecular host. This host binds specifical-
ly to the pyranine moiety, enabling the complex to traverse 
the cell membrane. Interestingly, none of the components, 
neither the host nor the guest, are able to cross the cell 
membrane by their own. 
Recent years have witnessed increased interest in the de-
velopment of efficient cell-penetrating molecular transport-
ers.1 Among the different strategies so far developed, those 
based on oligoarginine peptides are particularly effective,2,3 
and have led to many biological and biomedical applica-
tions.4 An appealing step forward in this field would be the 
development of responsive systems whose cell internaliza-
tion could be controlled using an external stimulus. Progress 
in this direction has been slow, and essentially limited to the 
temporary covalent attachment of negatively charged tails to 
the oligoarginine sequence through cleavable linkers. The 
polyanionic domain neutralizes the polycationic character of 
the peptide, thereby impairing its internalization; however 
the active cell penetrating peptide (CPP) is released upon 
application of a suitable external trigger, such as hydrogen 
peroxide,5 UV light,6 or certain tumor-associated proteases.7 
Although this strategy has raised expectations due to its 
potential biomedical applications,8 relying on the cleavage of 
a covalent linker limits the efficiency of the release, the selec-
tivity of the process, and the reversibility of the switch. Fur-
thermore, it inevitably leads to the generation of secondary 
polyanionic peptides that might have undesired effects. In 
this context, the development of stimuli-responsive cell 
internalization strategies that do not rely on covalent bond-
cleavage reactions represents an appealing goal.  
Anion recognition has been a topic of recent attention due to 
the essential functions of anions in biological systems.9 Metal 
organic self-assembly10 has allowed the generation of many 
new anion receptors.11 The application of these structures to 
biological systems is limited due to the toxicity of the metals 
and the instability of these species in the presence of com-
peting ligands such as chloride or thiols in the intracellular 
medium. Alternatively, organic containers are ideal candi-
dates due to their high stability and low toxicity.12 However, 
only a few covalent cages have been reported that are capa-
ble of encapsulating large anions in water with high affinity, 
and their biological applications are unknown.13  
Herein we present a novel approach to control the cell up-
take of oligoarginine CPPs based on the formation of a host-
guest supramolecular complex involving an anion recogni-
tion process. The strategy relies on the encapsulation of a 
negatively-charged pyranine attached to the N-terminus of a 
peptide containing an octaarginine CPP. Interestingly, none 
of the components—the encapsulating host or the pyranine-
peptide guest—are able to cross cell membranes in meaning-
ful amounts as separate units, but their association promotes 
an efficient cellular uptake of both partners.  
This approach was inspired by our recent discovery that the 
oligocationic covalent cage 1 (Figure 1) can selectively encap-
sulate the dye pyranine (pyr) with nanomolar affinity (KD ≈ 
1.2 nM).14 Considering that such an interaction might coun-
terbalance the negative charges of the pyranine fluorophore, 
we envisioned that it could compensate the presumable 
transport inhibitory effect of a pyranine-oligoglutamic oli-
goanion introduced at the N-terminus of an octaarginine 
CPP.  
 
 Figure 1. Left: Concept of the switching strategy: an Arg8 CPP 
electrostatically masked by a polyanionic pyranine-Glun 
domain is activated by the formation of a supramolecular 
host-guest complex between the pyranine and a positively 
charged polyamine cage (1).  Right: structures of pyranine 
(pyr), and the host cage 1, in which six N1,N1'-([3,3'-
bipyridine]-6,6'-diylbis(methylene))bis(propane-1,3-diamine) 
edges, sharing the terminal N3 amines at the vertices, form a 
tetrahedral cage. Only one edge of the tetrahedron cage is 
shown for clarity. 
As illustrated in Figure 1, pyr-Glun-Arg8 peptides might not 
cross membranes, however, addition of the cage 1 was hy-
pothesized to encapsulate the pyranine moiety, partly com-
pensating the negative charges of the inhibitory Glun linker 
and thereby generating a transport-active complex.15 
As shown in Scheme 1, the designed peptide shuttles (pyr–
EnR8) contain a oligoanionic domain connected to an oc-
taarginine CPP through a short and flexible Gly-Gly-Lys 
spacer. The anionic pyranine fluorophore (pyr) is attached to 
the N-terminus of the composite peptide sequences using a 
carboxylate derivative (pyr-CH2CO2H).  
The peptide conjugates were assembled following standard 
Fmoc solid phase peptide synthesis protocols,16 and the Lys 
residue in the spacer was incorporated with its side chain 
protected with an orthogonally cleavable Alloc group, so that 
it could be selectively removed in the solid phase to intro-
duce various functionalities,17 such as the tetramethylrhoda-
mine (TMR) fluorophore (Scheme 1). 
In addition to shuttles with 1 and 6 glutamic acids, we also 
synthesized control peptides lacking Glu residues (pyr-R8), 
as well as a pyr–E6R8 derivative containing the TMR fluoro-
phore attached to the Lys side chain (pyr-TMR-E6R8). The 
desired peptides were purified and characterized by LC-MS, 
and obtained in reasonable yields ranging from 15 to 30% 
(see the supporting information for details). 
 
Scheme 1. Synthesis of representative peptide derivatives 
used in this study, and structure of the control peptide pyr-
R8 (see the supporting information). TMR = 5-
carboxytetramethylrhodamine. 
Having the desired compounds in hand, we analyzed their 
cell internalization properties in mammalian Vero cells by 
taking advantage of the intrinsic emission properties of the 
pyranine dye. Thus, while pyranine (pyr) is not capable of 
crossing the cell membrane by itself (Figure 2, left), its modi-
fication with an octaarginine CPP yields a conjugate (pyr-R8) 
that is efficiently internalized in Vero cells upon incubation 
at 5 µM concentration (Figure 2, right).  
 
Figure 2. Fluorescence micrographies of Vero cells after 
incubation with 5 µM of pyranine (pyr, left), or pyr-R8 
(right) in PBS, for 30 min at 37 ºC, followed by double wash-
ing with PBS, pH 7.5.  
As hypothesized, the presence of only one glutamic acid in 
the oligoarginine conjugate (pyr-E1R8), led to a significant 
decrease in the cellular uptake (Figure 3, left). However, 
while pyr-E1R8 was still partially taken up by cells, the intro-
duction of six glutamic acid residues led to a complete inhi-
bition of the internalization, as can be deduced from the lack 
of significant intracellular emission for the conjugate pyr-
E6R8 (Figure 3, bottom left).  Importantly, addition of 1 equiv 
of the supramolecular cage 1 to pyr-E6R8 (5 µM, 30 min at 37 
ºC), led to a clear intracellular emission of the pyranine dye, 
which follows a similar endosomal localization to that ob-
served for pyr-R8 (Figure 3, right). These results are in 
agreement with the proposed hypothesis that the encapsula-
tion of the pyranine by the positively charged cage 1 leads to 
a supramolecular assembly with similar transport properties 
to those of pyr-R8. Quantifying the fluorescence at different 
times confirmed that the internalization rates increase upon 
addition of the cage to both pyr-E1R8 or pyr-E6R8 (Figure 
S23). 
 
Figure 3. Fluorescence micrographies of Vero cells after 
incubation with 5 µM of the pyranine conjugates in the ab-
sence (left) or presence (right) of 1 equiv of cage 1, after 30 
min at 37 ºC, and after washing twice with PBS, pH 7.5. Top: 
pyr–E1R8; Bottom: pyr–E6R8. 
Considering that previous fluorescence titrations of pyranine 
with the cage 1 showed that the pyranine emission is strongly 
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 quenched upon complexation,14 the above results suggest 
that the supramolecular complex may disassemble upon 
internalization. In any case, the cellular imaging results are 
consistent with the proposed model, in which the encapsula-
tion of the pyranine fluorophore by positively charged cage 1 
triggers the translocation of the supramolecular assembly. 
Importantly, cell viability assays confirmed that all peptides 
as well as cage 1 are essentially non-cytotoxic (Figure S25).  
In agreement with previous studies of the host-guest interac-
tion between the cage 1 and the pyranine moiety, a fluores-
cence titration of a PBS solution of pyr–E6R8 (1 µM, pH 7.5) 
with increasing concentration of cage 1 produces a series of 
spectra of decreasing emission intensity due to the quench-
ing of the pyranine fluorophore by the cage (Figure 4, left). 
Fitting of the titration curve to a 1:1 binding model (Figure 4, 
right),18 allowed to obtain a KD of approx. 278 nM, two orders 
of magnitude higher than that observed for the complex 
1/pyr (KD = 1.2 nM).
14 This lower affinity might be beneficial 
in terms of favoring reversible encapsulations and the disas-
sembly of the supramolecular complex after internalization, 
albeit this conclusion must be taken with caution owing to 
the complexity of the cellular environment. 
 
Figure 4. Left: Fluorescence emission of pyr–E6R8 (thick 
solid line) with increasing concentration of cage 1 in PBS 
buffer pH 7.5, λexc = 380 nm (grey lines). Right: emission 
profile with the best fit to a 1:1 model. 95% Confidence inter-
val plotted in grey. 
Although the fluorescence of the pyranine allowed the pre-
liminary analysis of the cell entrance capability of its CPP 
hybrids, the relatively low intensity of its blue emission ad-
vised the incorporation of a secondary probe with better 
emission properties (i.e., brighter and fluorescent at longer 
wavelengths). Therefore, we explored the performance of the 
tetramethylrhodamine derivative pyr–TMR-E6R8, which was 
synthesized as shown in Scheme 1. 
Gratifyingly, while pyr–TMR-E6R8 was not observed to in-
ternalize, as deduced from the lack of intracellular fluores-
cence, addition of the cage 1 promoted a bright red intracel-
lular fluorescence, emission that was mainly localized in 
endosomes (Figure 5, top). This observation is again con-
sistent with an efficient uptake of the peptide in the presence 
of the supramolecular cage. Importantly, the switching can 
be reproduced in other types of cells, including A549 human 
lung carcinoma cells and HeLa, which provided similar re-
sults (Figure S21). 
 
Figure 5. Top: Fluorescence micrographies of Vero cells after 
incubation with 5 µM pyr-TMR–E6R8 in the absence (left) or 
presence (right) of 1 equiv of cage, incubations for 30 min at 
37 ºC, and after washing twice with PBS, pH 7.5. Bottom: 
Confocal micrographies of Vero cells after incubation with 5 
µM pyr-TMR–E6R8 in the absence (left) or presence (right) 
of 1 equiv of cage, for 30 min at 37 ºC, without washing. 
On the other hand, a more detailed analysis using confocal 
microscopy and avoiding washing steps, clearly showed that, 
in the absence of the cage, the red emission of the TMR was 
located outside of the cells. However, addition of 1 equiv of 
the host 1 led to the formation of red fluorescent vesicles 
inside cells 30 min after the addition (Figure 5, bottom).  
In order to better understand the role of cage 1 in the cellular 
translocation of the complex, we also prepared a tetra-
methylrhodamine derivative of the cage, TMR–1, demon-
strating that it is possible to carry out a second post-
assembly modification of the initial cage (Figure 6, top).19 
Interestingly, the TMR-modified cage (TMR-1) showed a 
limited internalization into cells by itself. However, after the 
addition of pyr–E6R8 to the medium, we observed the ap-
pearance of intracellular emission, consistent with the inter-
nalization of the TMR-1/pyr-E6R8 complex (Figure 6, bot-
tom). In agreement with previous results, the emission was 
again mainly localized in endosomes, and fully colocalizes 
with that of the pyranine from the peptide shuttle (Figure 
S22). Therefore, the supramolecular host 1 not only triggers 
the activity of the octaarginine as a transporter, but can itself 
be also considered as a cargo. Therefore, this system repre-
sents an interesting case of supramolecular symbiosis, in 
which both partners, the host 1 and the pyr-E6R8 guest, act 
synergistically to yield an efficient supramolecular trans-
porter.  
Finally, addition of an excess (over 3 equiv) of pyranine to 
the mixture of 1 and pyr–E6R8, before incubation with the 
cells, led to an almost complete inhibition of the cell inter-
nalization (Figure S24). This result further confirms that the 
cellular translocation is mediated by the proposed host-guest 
interaction.  
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Figure 6. Top: Synthesis of TMR-1. Bottom: Fluorescence 
micrographies of Vero cells after incubation with 5 µM TMR–
1 in the absence (left) or presence (right) of 1 equiv of pyr–
E6R8, for 30 min at 37 ºC (double washing with PBS, pH 7.5). 
In conclusion, we have demonstrated that organic supramo-
lecular capsules can be used to regulate cellular uptake. The 
success of our strategy depends upon the cancellation of the 
cell membrane adhesiveness of an octaarginine transporter 
through introduction of an N-terminal polyanionic tether 
formed by glutamic acids and an anionic pyranine. Addition 
of the supramolecular host relieves the quenching effect of 
the polyanion and triggers the cell entrance. This strategy, 
which involves an uncommon synergic supramolecular ef-
fect, might find important applications to control the spatial 
and temporal release of drugs, dyes or other agents inside 
cells. Furthermore, since both components, the cage and the 
peptide, can be covalently modified to attach molecules, this 
methodology might allow to internalize two different drugs 
at the same time. 
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